Patients with
hematuria or who applied for cystoscopic control of proven
bladder cancer were prospectively enrolled in this study. Routine cytologic examination and
NMP22 test were performed on the voided urine sample obtained before the cystoscopy. The patients who had been diagnosed with
bladder cancer were categorized according to stage, grade, number, size of the
tumor and risk of the disease. Then the diagnostic performance of the
NMP22 and the cytology test, alone or in combination, were evaluated separately using ROC curves in the diagnosis and surveillance groups.
RESULTS: A total of 87 patients (87/136) were investigated because of
hematuria. The sensitivity, specificity, positive and, negative predictive values, and positive likelihood ratio (LR+) of the
NMP22 test were 70, 80, 68, 81, and 3.42%, respectively. While, the sensitivity, specificity, positive and, negative predictive values, and positive likelihood ratio (LR+) of the cytology examination were 27, 96, 82, 68, and 7.36%, respectively. There were 49 patients in the
bladder cancer group. The sensitivity, specificity, positive, and negative predictive values and positive likelihood ratio (LR+) of the
NMP22 test in these patients were 33, 76, 31, 78 and 1.37%, respectively. The sensitivity, specificity, positive and, negative predictive values, and positive likelihood ratio (LR+) of the cytology examination were 25%, 97%, 75%, 80% and 9.25, respectively.
CONCLUSION: